CG Oncology, Inc. Common stock (CGON) Revenue History
Annual and quarterly revenue from 2021 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
CGON Revenue Analysis (2021–2024)
As of February 28, 2026, CG Oncology, Inc. Common stock (CGON) generated trailing twelve-month (TTM) revenue of $2.2 million, reflecting explosive growth of +3774.4% year-over-year. The most recent quarter (Q3 2025) recorded $1.7 million in revenue.
Looking at the longer-term picture, CGON's historical revenue data shows a 3-year CAGR of -52.1%. The company achieved its highest annual revenue of $10.4 million in 2021.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), CGON has outperformed the peer group in terms of revenue growth. Compare CGON vs INCY →
Peer Comparison
Compare CGON's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CGONCurrent | $2M | +3774.4% | - | -10067.3% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.1M | +458.3% | $1.1M | 100.0% | $-114,666,000 | -10067.3% |
| 2023 | $204K | +6.8% | $204K | 100.0% | $-55,449,000 | -27180.9% |
| 2022 | $191K | -98.2% | $176K | 92.1% | $-35,246,000 | -18453.4% |
| 2021 | $10.4M | - | $10.3M | 99.9% | $-12,606,000 | -121.7% |
See CGON's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGON Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CGON vs AGIO
See how CGON stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CGON's revenue growth accelerating or slowing?
CGON revenue is accelerating at +3774.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $2M. Growth momentum has increased versus prior periods.
What is CGON's long-term revenue growth rate?
CG Oncology, Inc. Common stock's 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +3774.4% is above this long-term average.
How is CGON's revenue distributed by segment?
CGON reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2024 are available for download. Segment mix reveals concentration and diversification trends.